EyePoint, Inc. EYPT

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.

WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,00

Monday - Lumentum Holdings What’s the full story? Evercore initiates Lumentum Lumentum Holdings Inc (NASDAQ:LITE) at Outperform with an $1,100 target. The AI revolution has a supply-chain coronary: silicon processors run fast, but data can’t move between them. Connecting these compute clusters requires Indium Phosphide lasers—a scarce, capital-intensive material where demand outpaces supply by 30%. LITE holds the choke point, shifting pricing power and margin upstream to vertically integrated in

EyePoint just saw its assessed fair value reset sharply, dropping from US$40.54 to US$25.91, which signals a major rethink of where analysts see the stock’s long term potential. This reset lines up with a split analyst view after the LUGANO Phase 3 miss, wide ranging new price targets, and fresh questions about Duravyu and execution risk. In the sections ahead, you will see what is driving the changing narrative around EyePoint and how to track the story as new data arrives. Stay updated as...

Markets took a beating Tuesday as war tensions, surging oil, and the September curse hammered stocks, bonds, and gold all at once. Find out which stocks Wall Street upgraded, downgraded, or initiated fresh coverage on as analysts scramble to reposition heading into a brutal stretch.

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences: Citi 2026 Biopharma Back to School ConferenceForum: Fireside ChatDate: September 9, 2026Time: 8:00 am ETCantor Global Healthcare Conference 2026Forum: Fireside ChatDate: September 10, 2

Graham Holdings (GHC) was a bearish price surprise on Monday, down 2.2%. At the same time, Biglari Holdings (BH.A) was a bullish price surprise, up 3.56%. Both holding companies have diversified businesses. The bear is the bet.

EyePoint's (EYPT) phase 3 Lugano trial's failure to meet its primary endpoint raises concerns about

GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.

RBC Capital said that even if EyePoint’s second Phase 3 study delivers positive results, questions would remain over whether the U.S. Food and Drug Administration would approve the treatment based on a single trial.

Interest in EyePoint (EYPT) has focused on fresh topline data from the Phase 3 LUGANO trial of DURAVYU for wet age related macular degeneration, after the study missed its primary non inferiority endpoint but showed meaningful secondary outcomes. See our latest analysis for EyePoint. The LUGANO update has coincided with a sharp reset in EyePoint's share price. The stock closed at $4.87 after a 1 day share price return that declined 66.98%. This contributed to a year to date share price return...

EyePoint Pharmaceuticals recently reported that its pivotal Phase 3 LUGANO trial of DURAVYU for wet age-related macular degeneration did not achieve the primary non-inferiority endpoint versus aflibercept, while posting clinically meaningful gains in treatment burden reduction and maintaining a favorable safety profile. The company now faces a critical juncture as it pivots investor focus to the upcoming LUCIA Phase 3 readout and a potential US Food and Drug Administration filing in 2027,...

The sell-offs followed a failed trial, a massive recall, and a CEO's exit.

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.